Literature DB >> 14660739

Complement system on the attack in autoimmunity.

John P Atkinson1.   

Abstract

The antiphospholipid syndrome is characterized clinically by fetal loss and thrombosis and serologically by the presence of autoantibodies to lipid-binding proteins. In a model of this procoagulant condition in which these antibodies are injected into pregnant mice, fetal loss was prevented by blocking of complement activation. Specifically, interaction of complement component 5a (C5a) with its receptor is necessary for thrombosis of placental vasculature. Inhibition of complement activation may have a therapeutic role in this disease.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14660739      PMCID： PMC281650          DOI： 10.1172/JCI20309

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


  18 in total

Review 1.  Evidence-based management of thrombosis in the antiphospholipid antibody syndrome.

Authors:  Michelle Petri
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

2.  Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo.

Authors:  S S Pierangeli; M Colden-Stanfield; X Liu; J H Barker; G L Anderson; E N Harris
Journal:  Circulation       Date:  1999-04-20       Impact factor: 29.690

3.  Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme.

Authors:  I Matsumoto; A Staub; C Benoist; D Mathis
Journal:  Science       Date:  1999-11-26       Impact factor: 47.728

4.  Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis.

Authors:  B T Wipke; P M Allen
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

5.  Expression and function of C5a receptor in mouse microvascular endothelial cells.

Authors:  Ines J Laudes; Jeffrey C Chu; Markus Huber-Lang; Ren-Feng Guo; Niels C Riedemann; J Vidya Sarma; Fakhri Mahdi; Hedwig S Murphy; Cecilia Speyer; Kristina T Lu; John D Lambris; Firas S Zetoune; Peter A Ward
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

6.  Arthritis critically dependent on innate immune system players.

Authors:  Hong Ji; Koichiro Ohmura; Umar Mahmood; David M Lee; Frans M A Hofhuis; Susan A Boackle; Kazue Takahashi; V Michael Holers; Mark Walport; Craig Gerard; Alan Ezekowitz; Michael C Carroll; Michael Brenner; Ralph Weissleder; J Sjef Verbeek; Veronique Duchatelle; Claude Degott; Christophe Benoist; Diane Mathis
Journal:  Immunity       Date:  2002-02       Impact factor: 31.745

7.  How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease.

Authors:  Isao Matsumoto; Mariana Maccioni; David M Lee; Madelon Maurice; Barry Simmons; Michael Brenner; Diane Mathis; Christophe Benoist
Journal:  Nat Immunol       Date:  2002-03-18       Impact factor: 25.606

8.  Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome.

Authors:  Anna Richards; Elizabeth J Kemp; M Kathryn Liszewski; Judith A Goodship; Anne K Lampe; Ronny Decorte; M Hamza Müslümanoğlu; Salih Kavukcu; Guido Filler; Yves Pirson; Leana S Wen; John P Atkinson; Timothy H J Goodship
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-17       Impact factor: 11.205

9.  Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome.

Authors:  Tamara Manuelian; Jens Hellwage; Seppo Meri; Jessica Caprioli; Marina Noris; Stefan Heinen; Mihaly Jozsi; Hartmut P H Neumann; Giuseppe Remuzzi; Peter F Zipfel
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

10.  Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells.

Authors:  Maria L Barilla-LaBarca; M Kathryn Liszewski; John D Lambris; Dennis Hourcade; John P Atkinson
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422
View more
  6 in total

1.  The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation.

Authors:  M Harboe; G Ulvund; L Vien; M Fung; T E Mollnes
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

2.  Tracing the molecular pathogenesis of antiphospholipid syndrome.

Authors:  Hartmut Weiler
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

3.  Blockade of autoantibody-initiated tissue damage by using recombinant fab antibody fragments against pathogenic autoantigen.

Authors:  Gang Wang; Hideyuki Ujiie; Akihiko Shibaki; Wataru Nishie; Yasuki Tateishi; Kazuhiro Kikuchi; Qiang Li; James R McMillan; Hiroshi Morioka; Daisuke Sawamura; Hideki Nakamura; Hiroshi Shimizu
Journal:  Am J Pathol       Date:  2009-12-30       Impact factor: 4.307

4.  C5a induces caspase-dependent apoptosis in brain vascular endothelial cells in experimental lupus.

Authors:  Supriya D Mahajan; Vincent M Tutino; Yonas Redae; Hui Meng; Adnan Siddiqui; Trent M Woodruff; James N Jarvis; Teresa Hennon; Stanley Schwartz; Richard J Quigg; Jessy J Alexander
Journal:  Immunology       Date:  2016-07-11       Impact factor: 7.397

5.  Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) Among Patients With Antiphospholipid Antibodies (aPL).

Authors:  Stephanie L Savelli; Robert A S Roubey; Kathryn J Kitzmiller; Danlei Zhou; Haikady N Nagaraja; Evan Mulvihill; Fatima Barbar-Smiley; Stacy P Ardoin; Yee Ling Wu; Chack-Yung Yu
Journal:  Front Immunol       Date:  2019-05-07       Impact factor: 7.561

Review 6.  The alternative complement pathway revisited.

Authors:  Morten Harboe; Tom Eirik Mollnes
Journal:  J Cell Mol Med       Date:  2008-04-15       Impact factor: 5.310
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.